Table 1.

Baseline data for study participants

Characteristics	Patients (n=1,000)
Mean age ± SD, years	23.9±15.4
Mean age at initial blood transfusion ± SD, years
All subjects	5.9±10.8
Hb E/beta-thalassemia	5.8±10.0
Beta-thalassemia major	2.4±4.6
Other	9.1±15.6
Mean pre-transfused Hb ±SD, g/dL	8.1±1.4
Mean serum ferritin ± SD, ng/mL	2,161±2,179
Gender, n (%)
Female	551 (55.1)
Male	449 (44.9)
Splenectomy, n (%)
No	736 (73.6)
Yes	264 (26.4)
Current iron chelation, n (%)
None	62 (6.2)
Deferoxamine monotherapy	12 (1.2)
Deferiprone monotherapy	485 (48.5)
Deferasirox monotherapy	237 (23.7)
Combined Deferoxamine + Deferiprone	78 (7.8)
Combined Deferoxamine + Deferasirox	55 (5.5)
Combined Deferiprone + Deferasirox	71 (7.1)
Phenotype group, n (%)
Hb E/beta-thalassemia	738 (73.8)
Beta-thalassemia major	113 (11.3)
Hb H disease with Hb CS	65 (6.5)
EABart’s disease†	23 (2.3)
EABart’s disease with HbCS‡	44 (4.4)
EFBart’s disease§	3 (0.3)
EFBart’s disease with HbCS¶	3 (0.3)
Other	11 (1.1)

Abbreviation: Hb, hemoglobin; Hb CS, hemoglobin Constant Spring.

^†Compound heterozygous Hb H and heterozygous Hb E.

^‡Compound heterozygous Hb H with Hb CS and heterozygous Hb E.

^§Compound heterozygous Hb H and homozygous Hb E.

^¶Compound heterozygous Hb H with Hb CS and homozygous Hb E.